Oryzon Genomics (STU:ORN) Short-Term Debt : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Oryzon Genomics Short-Term Debt?

Oryzon Genomics's Short-Term Debt for the quarter that ended in Mar. 2024 was €0.00 Mil.

Oryzon Genomics's quarterly Short-Term Debt increased from Sep. 2023 (€7.42 Mil) to Dec. 2023 (€10.36 Mil) but then declined from Dec. 2023 (€10.36 Mil) to Mar. 2024 (€0.00 Mil).

Oryzon Genomics's annual Short-Term Debt increased from Dec. 2021 (€3.43 Mil) to Dec. 2022 (€10.49 Mil) but then declined from Dec. 2022 (€10.49 Mil) to Dec. 2023 (€10.36 Mil).

Oryzon Genomics Short-Term Debt Historical Data

The historical data trend for Oryzon Genomics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oryzon Genomics Short-Term Debt Chart

Oryzon Genomics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

5.74

3.83

3.43

10.49

10.36

Oryzon Genomics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															-	9.33	7.42	10.36	-

Oryzon Genomics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Oryzon Genomics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Oryzon Genomics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Oryzon Genomics (STU:ORN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oryzon Genomics SA (STU:ORN) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

ORYZF:USA ORY:Spain

Address

Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940

Website

http://www.oryzon.com

Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.